FIS
46
-9
COST
54
4
C
54
4
WMB
63
3
CTAS
53
3
VRTX
62
10
AA
47
4
WDC
44
3
BA
48
-5
DIS
52
3
DD
64
9
OKE
68
4
BXP
49
2
AAP
30
3
M
30
2
FLR
60
4
EXR
57
7
HP
41
5
GME
57
2
IPG
50
2
FIS
46
-9
COST
54
4
C
54
4
WMB
63
3
CTAS
53
3
VRTX
62
10
AA
47
4
WDC
44
3
BA
48
-5
DIS
52
3
DD
64
9
OKE
68
4
BXP
49
2
AAP
30
3
M
30
2
FLR
60
4
EXR
57
7
HP
41
5
GME
57
2
IPG
50
2
Financhill
Back

Zevra Therapeutics 10K Form

Buy
67

ZVRA
Zevra Therapeutics

Last Price:
8.81
Seasonality Move:
3.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $27.46M
Cash Flow: $-19.11M
Price / Cash Flow: 0
Annual Sales: $0.77
Price / Book: 13.95

Profitability

EPS (TTM): -1.68000
Net Income (TTM): $-65.75M
Gross Margin: $24.52M
Return on Equity: -117.77%
Return on Assets: -46.14%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for ZVRA is 89.28%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 124.96% of Gross Profit Margin.
  • The Research & Development expenses have been 144.95% of Revenue.
  • The Interest Expense is -3.26% of Operating Income.
  • The Net Earning history of ZVRA is -167.69% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 1.8
Current Ratio: 2
Quick Ratio: 1.91

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ZVRA Technical Analysis vs Fundamental Analysis

Buy
67
Zevra Therapeutics (ZVRA) is a Buy

Is Zevra Therapeutics a Buy or a Sell?